Solid Tumor Testing Market Size to Reach USD 12.1 Billion by 2031 | Key Trends & Forecasts
Global solid tumor testing market is
undergoing rapid transformation as oncology shifts decisively toward precision
medicine and genomic-guided therapies. Valued at USD 6.8 billion in 2024,
the market is projected to reach USD 12.1 billion by 2031, expanding at
a strong CAGR of 8.5%, driven by rising cancer incidence, personalized
treatment pathways, and technological advancements in molecular testing.
Read
more on https://www.24lifesciences.com/solid-tumor-testing-market-9012
Emerging
Healthcare Trends Reshaping Solid Tumor Diagnostics
The solid tumor testing market is
benefiting from a new wave of healthcare innovation in 2025. Growing adoption
of next-generation sequencing (NGS), expansion of AI-supported
clinical diagnostics, and deeper integration of molecular profiling in
oncology workflows are creating a more efficient and data-driven cancer
care ecosystem.
AI-assisted pathology systems and
predictive diagnostic algorithms are improving early detection accuracy, while
tele-oncology platforms are enabling wider access to molecular testing in
remote and underserved regions. Global momentum toward personalized care,
coupled with strong advancements in tumor biomarker discovery, is accelerating
the shift toward tailored therapeutic decisions.
Key
Market Drivers Supporting Global Growth
Several powerful forces are shaping
the market trajectory:
- Technological Advancements: NGS, PCR, and immunohistochemistry are enabling broader
and more detailed tumor profiling with faster turnaround times.
- Rising Global Cancer Burden: Increasing incidence across lung, breast, colorectal,
and prostate cancers is fueling diagnostic demand.
- Expanding Precision Oncology Ecosystem: Targeted therapies and immunotherapies rely on
accurate biomarker identification, making molecular testing indispensable.
- Government & Institutional Initiatives: National cancer programs and public-private
partnerships are strengthening genomic infrastructure.
- Shift Toward Value-Based Care: Hospitals and oncology networks are prioritizing
accurate diagnostics to support cost-effective and personalized treatment
plans.
Together, these factors reinforce
solid tumor testing as a foundational pillar of modern oncology.
Download the full dataset https://www.24lifesciences.com/download-sample/9012/solid-tumor-testing-market
Competitive
Landscape: Leading Companies Driving Innovation
Key companies shaping global
industry dynamics include:
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Danaher Corporation (Beckman Coulter)
These industry leaders continue to
invest heavily in genomic technologies, liquid biopsy development, companion
diagnostics, and integrated oncology platforms. Strategic collaborations,
R&D expansion, and clinical workflow automation remain central to their
long-term growth priorities.
Segment
Insights & Regional Market Overview
By
Type
Non-Conventional Testing dominates the market, fueled by widespread adoption of
advanced molecular diagnostics, sequencing-based platforms, and
biomarker-driven testing models. These technologies outperform traditional
histopathology by offering deeper insights into tumor genetics and actionable
mutations.
By
Application
Hospitals remain the leading application segment due to their role as
primary cancer care hubs. High patient volumes, comprehensive oncology centers,
and access to multidisciplinary teams underpin this dominance.
By
End User
Oncologists constitute the largest end-user group, relying on detailed
tumor profiling to guide treatment planning, therapy selection, and disease
monitoring.
By
Technology Platform
Next-Generation Sequencing (NGS) stands as the most influential platform, enabling
multi-gene panel testing, whole-exome and whole-genome sequencing, and
high-throughput biomarker analysis.
By
Tumor Profiling Purpose
Therapeutic Selection leads due to the rising global use of targeted therapies
and immunotherapies that require precise biomarker validation before
initiation.
Explore
analytics https://www.24lifesciences.com/solid-tumor-testing-market-9012
Regional
Overview
- North America
remains the global leader, driven by advanced precision medicine programs,
high healthcare spending, and rapid adoption of NGS and companion
diagnostics.
- Europe
follows with strong institutional support, well-established cancer care
frameworks, and increasing standardization under evolving IVDR guidelines.
- Asia-Pacific
is the fastest-growing region, powered by rising cancer incidence,
expanding genomic infrastructure, and government-led innovation in China
and Japan.
- South America
shows steady growth, led by Brazil, as oncology centers modernize
diagnostic capabilities.
- Middle East & Africa presents a mixed landscape — with high-end adoption in
GCC nations and early-stage development across parts of Africa.
Can
AI-Driven Care Models Reshape the Future of Solid Tumor Testing?
AI-enabled clinical decision
systems, digital pathology, and real-time biomarker analytics are expected to
redefine how clinicians diagnose, treat, and monitor solid tumors in the coming
decade. Predictive modeling, automated image interpretation, and cloud-based
genomic platforms will enhance the precision, accessibility, and speed of
cancer diagnostics globally.
Key
Benefits of the Full Report
- Extensive segmentation and competitive analysis
- Accurate CAGR-based market forecasts through 2031
- Insight into technology adoption across global markets
- Emerging opportunities in precision oncology and
genomic testing
- Strategic guidance for investors and healthcare
organizations
View
market insight https://www.24lifesciences.com/solid-tumor-testing-market-9012
Future
Perspective
As healthcare systems worldwide
accelerate their transition toward personalized cancer care, the solid tumor
testing market is positioned for significant expansion. Advancements in
sequencing technologies, ongoing biomarker discoveries, and robust oncology
investments will continue to unlock new growth avenues for stakeholders across
diagnostics, biopharma, and clinical care ecosystems.
Explore
Life sciences Related Ongoing Coverage in Healthcare Domain:
1.5T
Helium-Free MRI System Market
Prostaglandin
endoperoxide Synthase 2 (COX-2) ELISA Kit Market
Ribbon
Retractor Market
Long
Term Care Provider Market
PSA Test Market
Cervical
Dilator Market
Varicella
Vaccine Market
Urine Analyzer
Market
Bladder
Scanners Market
Cardiac
Monitoring & Cardiac Rhythm Management Market
About 24lifesciences
Founded in 2017, 24LifeScience has
emerged as a trusted research and analytics partner for organizations operating
within the global life sciences and chemical industries. Our core mission is to
provide intelligent, future-ready insights that help clients stay ahead in an
increasingly complex and innovation-driven market
International: +1(332) 2424 294 | Asia: +91 9425150513 (Asia)
Website: http://www.24lifesciences.com
Follow us on
LinkedIn: http://www.linkedin.com/company/lifesciences24

Comments
Post a Comment